Furthermore, treatments targeting galectin-3 [16] and the mineralocorticoid receptor [17] have been shown to mitigate endothelial inflammation caused by the virus, pointing towards innovative strategies for treating COVID-19-related complications 17. Here, LGALS3 is linked to COVID-19.